Author/Editor		Janžič, Urška; Bidovec, Urška; Mohorčič, Katja; Mrak, Loredana; Fokter Dovnik, Nina; Ivanović, Marija; Ravnik, Maja; Čakš, Marina; Škof, Erik; Debeljak, Jerneja; Korošec, Peter; Rijavec, Matija
Title		Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination
Type		članek
Vol. and No.		Letnik 18, št. 23
Publication year		2022
Volume		str. 2537‐2550
ISSN		1479-6694 - Future oncology (London, England)
Language		eng
Abstract		Background: SARS-CoV-2 vaccination in cancer patients is crucial to prevent severe COVID-19 disease course. Methods: This study assessed immunogenicity of cancer patients on active treatment receiving mRNA-based SARS-CoV-2 vaccine by detection of anti-SARS-CoV-2 S1 IgG antibodies in serum, before, after the first and second doses and 3 months after a complete primary course of vaccination. Results were compared with healthy controls. Results: Of 112 patients, the seroconversion rate was 96%. A significant reduction in antibody levels was observed 3 months after vaccination in patients receiving immune checkpoint inhibitors versus control participants (p < 0.001). Adverse events were mostly mild. Conclusion: Immunogenicity after mRNA-based vaccine in cancer patients is adequate but influenced by the type of anticancer therapy. Antibody levels decline after 3 months, and thus a third vaccination is warranted.
Keywords		onkološko zdravljenje imunogenost osnovno cepljenje mRNA čvrsti tumorji anticancer treatment immunogenicity mRNA-based vaccination solid cancer